$KURA ready for new 52 week highs on volume
Looking forward to FLT3 combo data at ASH (gilteritinib in r/r AML, quizartinib quadruplet in frontline)
Safety/tolerability = key differentiator in menin
Enrolling quickly & mgmt wants to share data as soon as able (usual caveats)